Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Ischaemic stroke; Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms DARING-AF
Most Recent Events
- 16 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Feb 2016 New trial record